Literature DB >> 8624872

Myocardial beta adrenoceptors and left ventricular function in hypertrophic cardiomyopathy.

L Choudhury1, S Guzzetti, D C Lefroy, P Nihoyannopoulos, W J McKenna, C M Oakley, P G Camici.   

Abstract

OBJECTIVE: To assess the relation between left ventricular function and myocardial beta adrenoceptor density.
METHODS: 17 patients with hypertrophic cardiomyopathy, six with and 11 without heart failure, were studied. Left ventricular function was assessed by echocardiography, and myocardial beta adrenoceptors by positron emission tomography. Patient data were compared with those obtained in normal controls.
RESULTS: Myocardial beta adrenoceptor density in the 17 patients was 7.00 (SD 1.90) pmol/g v 11.50 (2.18) pmol/g in normal controls (P < 0.01). beta Adrenoceptor density in the six patients with left ventricular failure was 5.61 (0.88) pmol/g v 7.71 (1.86) pmol/g in the 11 patients with normal ventricular function (P < 0.05), and there was a significant correlation (r = 0.52; P < 0.05) between left ventricular fractional shortening and myocardial beta adrenoceptor density. A positive correlation (r = 0.51; P < 0.05) was also found between myocardial beta adrenoceptor density and the E/A transmitral flow ratio, an index of left ventricular diastolic function.
CONCLUSIONS: There is myocardial beta adrenoceptor downregulation in patients with hypertrophic cardiomyopathy with or without signs of heart failure.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8624872      PMCID: PMC484222          DOI: 10.1136/hrt.75.1.50

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  23 in total

1.  Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy.

Authors:  P Spirito; B J Maron; R O Bonow; S E Epstein
Journal:  Am J Cardiol       Date:  1987-07-01       Impact factor: 2.778

2.  Myocardial hypertrophy produced by chronic infusion of subhypertensive doses of norepinephrine in the dog.

Authors:  M M Laks; F Morady; H J Swan
Journal:  Chest       Date:  1973-07       Impact factor: 9.410

Review 3.  Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1).

Authors:  B J Maron; R O Bonow; R O Cannon; M B Leon; S E Epstein
Journal:  N Engl J Med       Date:  1987-03-26       Impact factor: 91.245

4.  Patterns of inheritance in hypertrophic cardiomyopathy: assessment by M-mode and two-dimensional echocardiography.

Authors:  B J Maron; P F Nichols; L W Pickle; Y E Wesley; J J Mulvihill
Journal:  Am J Cardiol       Date:  1984-04-01       Impact factor: 2.778

5.  Two-dimensional real-time ultrasonic imaging of the heart and great vessels. Technique, image orientation, structure identification, and validation.

Authors:  A J Tajik; J B Seward; D J Hagler; D D Mair; J T Lie
Journal:  Mayo Clin Proc       Date:  1978-05       Impact factor: 7.616

6.  Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in patients with hypertrophic cardiomyopathy.

Authors:  B J Maron; P Spirito; K J Green; Y E Wesley; R O Bonow; J Arce
Journal:  J Am Coll Cardiol       Date:  1987-10       Impact factor: 24.094

7.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts.

Authors:  M R Bristow; R Ginsburg; W Minobe; R S Cubicciotti; W S Sageman; K Lurie; M E Billingham; D C Harrison; E B Stinson
Journal:  N Engl J Med       Date:  1982-07-22       Impact factor: 91.245

8.  Progression of hypertrophic cardiomyopathy into a hypokinetic left ventricle: higher incidence in patients with midventricular obstruction.

Authors:  S Fighali; Z Krajcer; S Edelman; R D Leachman
Journal:  J Am Coll Cardiol       Date:  1987-02       Impact factor: 24.094

9.  Myocardial catecholamines in hypertrophic and dilated (congestive) cardiomyopathy: a biopsy study.

Authors:  C Kawai; Y Yui; T Hoshino; S Sasayama; A Matsumori
Journal:  J Am Coll Cardiol       Date:  1983-11       Impact factor: 24.094

10.  Cardiac norepinephrine kinetics in hypertrophic cardiomyopathy.

Authors:  J E Brush; G Eisenhofer; M Garty; R Stull; B J Maron; R O Cannon; J A Panza; S E Epstein; D S Goldstein
Journal:  Circulation       Date:  1989-04       Impact factor: 29.690

View more
  11 in total

Review 1.  Positron emission tomography and myocardial imaging.

Authors:  P G Camici
Journal:  Heart       Date:  2000-04       Impact factor: 5.994

Review 2.  Nuclear cardiac imaging in hypertrophic cardiomyopathy.

Authors:  Jamshid Shirani; Vasken Dilsizian
Journal:  J Nucl Cardiol       Date:  2011-02       Impact factor: 5.952

3.  Chronic sympathetic activation promotes downregulation of β-adrenoceptor-mediated effects in the guinea pig heart independently of structural remodeling and systolic dysfunction.

Authors:  Ewa Soltysinska; Stefanie Thiele; Søren Peter Olesen; Oleg E Osadchii
Journal:  Pflugers Arch       Date:  2011-08-03       Impact factor: 3.657

Review 4.  Biophysical Derangements in Genetic Cardiomyopathies.

Authors:  Melissa L Lynn; Sarah J Lehman; Jil C Tardiff
Journal:  Heart Fail Clin       Date:  2018-04       Impact factor: 3.179

5.  Abnormal heart rate regulation in murine hearts with familial hypertrophic cardiomyopathy-related cardiac troponin T mutations.

Authors:  Jesus Jimenez; Jil C Tardiff
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-12-03       Impact factor: 4.733

Review 6.  The many faces of hypertrophic cardiomyopathy: from developmental biology to clinical practice.

Authors:  Iacopo Olivotto; Francesca Girolami; Stefano Nistri; Alessandra Rossi; Luigi Rega; Francesca Garbini; Camilla Grifoni; Franco Cecchi; Magdi H Yacoub
Journal:  J Cardiovasc Transl Res       Date:  2009-10-27       Impact factor: 4.132

7.  Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations.

Authors:  Vasco Sequeira; Paul J M Wijnker; Louise L A M Nijenkamp; Diederik W D Kuster; Aref Najafi; E Rosalie Witjas-Paalberends; Jessica A Regan; Nicky Boontje; Folkert J Ten Cate; Tjeerd Germans; Lucie Carrier; Sakthivel Sadayappan; Marjon A van Slegtenhorst; Ruud Zaremba; D Brian Foster; Anne M Murphy; Corrado Poggesi; Cris Dos Remedios; Ger J M Stienen; Carolyn Y Ho; Michelle Michels; Jolanda van der Velden
Journal:  Circ Res       Date:  2013-03-18       Impact factor: 17.367

8.  Coronary recanalisation, myocardial viability, and ventricular remodelling after infarction.

Authors:  P G Camici
Journal:  Heart       Date:  2005-04       Impact factor: 5.994

9.  Divergent effects of adrenaline in human induced pluripotent stem cell-derived cardiomyocytes obtained from hypertrophic cardiomyopathy.

Authors:  Chandra Prajapati; Marisa Ojala; Katriina Aalto-Setälä
Journal:  Dis Model Mech       Date:  2018-02-26       Impact factor: 5.758

10.  Heart rate recovery in patients with hypertrophic cardiomyopathy.

Authors:  Vimal Patel; Christopher H Critoph; Malcolm C Finlay; Bryan Mist; Pier D Lambiase; Perry M Elliott
Journal:  Am J Cardiol       Date:  2013-12-25       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.